¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Prostaglandins Other Lipid Mediat"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® lipid ÇÑ±Û ÁöÁú
¼³¸í   
  »ý¹°Ã¼ ¾È¿¡ Á¸ÀçÇϸ砹°¿¡ ³ìÁö ¾Æ´ÏÇϰí, À¯±â¿ë¸Å¿¡ ³ì´Â À¯±âÈ­ÇÕ¹°À» ÅëÆ²¾î À̸£´Â ¸». Á¼Àº Àǹ̷δ ¹°¿¡ ³ìÁö ¾Ê°í ¾ËÄÚ¿Ã, ÄÝ·Î·ÎÆ÷¸§À̳ª ¿¡Å׸£, º¥Á¨ µîÀÇ ºñ±Ø¼º¿ë¸Å¿¡ ³ì´Â Áö¹æ»êÀÇ ¿¡½ºÅ׸£·Î »ýü¿¡ ÀÌ¿ëµÇ´Â À¯±âÈ­ÇÕ¹°ÀÌ´Ù. ´Ü¼øÁöÁú, º¹ÇÕÁöÁú(ÀÎÁöÁú, ´çÁöÁú, Áö´Ü¹é) ¹× À¯µµÁöÁú(ÁöÁúÀÇ °¡¼öºÐÇØ»ê¹°)·Î ºÐ·ùµÈ´Ù. Æ¯È÷ Áß¼ºÁö¹æÀº Áö¹æ»ê°ú ±Û¸®¼¼¸°°úÀÇ ¿¡½ºÅ׸£·Î ´Ü¹éÁú°ú ´ç°ú ÇÔ²² »ýüÀÇ Áֿ伺ºÐ ¹× ¿¡³ÊÁö¿øÀ¸·Î¼­ Áß¿äÇÏ´Ù. ±¤ÀǷδ ½ºÅ×·ÎÀ̵堵îÀ» Æ÷ÇÔÇØ¼­ È£¸£¸ó, ºñŸ¹Î ·ù·Î¼­ ÀÛ¿ëÇϴ °Í µîÀ¸·Î ´Ù¾çÇÑ »ý¸®ÇÐÀû ±â´ÉÀ» ´ã´çÇϰí ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • lipid
    ÁöÁú
  • lipid granule
    Áö¹æ°ú¸³
  • lipid infiltration
    ÁöÁúħÀ±
  • lipid layer
    ÁöÁúÃþ
  • lipid pneumonia
    ÁöÁúÆó·Å
  • lipid proteinosis
    ÁöÁú´Ü¹éÁõ
  • lipid solubility
    ÁöÁú¿ëÇØµµ
  • lipid storage disease
    ÁöÁúÃàÀûº´
  • lipid-soluble
    Áö¿ë¼º-
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • lipid
    ÁöÁú
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • lipid storage disease
    ÁöÁúÃàÀûº´
  • lipid granule
    Áö¹æ°ú¸³
  • lipid hypothesis
    ÁöÁú°¡¼³
  • lipid infiltration
    ÁöÁúħÀ±
  • lipid
    ÁöÁú
  • lipid-soluble
    Áö¿ë¼º-
  • lipid layer
    ÁöÁúÃþ
  • lipid pneumonia
    ÁöÁúÆó·Å
  • lipid proteinosis
    ÁöÁú´Ü¹éÁõ
  • lipid solubility
    ÁöÁú¿ëÇØµµ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Dorfman-Chanarin syndrome = neutral lipid storage disease
    Áß¼ºÁö¹æÃàÀûÁõ
  • Lipid Research Clinic
    ÁöÁú¿¬±¸Áø·á¼Ò
  • Lipid bilayer
    Áö¹æÀÌÁßÃþ(ò·Û¸ì£ñìöµ)
  • free radical formation,lipid peroxidation
    ÀÚÀ¯ ·¡µðÄ® Çü¼º, ÁöÁú °ú»êÈ­(ò·òõ Φ߫ûù)
  • granule, lipid
    Áö¹æ°ú¸³
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • atypical, mixed or other personality
    ºñÁ¤Çü ³»Áö È¥ÀçÇü ¶Ç´Â ±âŸ ÀΰÝ
  • shock and other somatic treatment
    Ãæ°Ý ¹× ±âŸ ½Åüġ·á
  • blood lipid
    Ç÷¾×ÁöÁú(úìäûò·òõ).
  • fecal lipid
    ºÐº¯Áö¹æ
  • free radical formation,lipid peroxidation
    ÀÚÀ¯ ·¡µðÄ® Çü¼º, ÁöÁú °ú»êÈ­(ò·òõ Φ߫ûù)
  • granule, lipid
    Áö¹æ°ú¸³
  • lipid
    ÁöÁú(ò·òõ)
  • lipid
    ÁöÁú(ò·òõ).
  • lipid
    ÁöÁú(ò·òõ)
  • lipid A
    ÁöÁú A
  • lipid cell tumor
    ÁöÁú¼¼Æ÷ Á¾¾ç(¡­á¬øà ðþåË)
  • lipid drop
    Áö¹æ¹æ¿ï
  • lipid droplet
    Áö¹æ¹æ¿ï
  • lipid hypothesis
    ÁöÁú°¡¼³
  • lipid infiltration
    ÁöÁúħÀ±(¡­öÕëÈ).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Lipid drop
    Áö¹æ¹æ¿ï
    [¿¾ ¿ë¾î] Áö¹æ¼ÒÀû
  • Lipid droplet
    Áö¹æ¹æ¿ï
    [¿¾ ¿ë¾î] Áö¹æ¼ÒÀû
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • bare lipid membrane
    ¾Ë¸ö ÁöÁú¸·(ò·òõد)
  • bilayer lipid membrane
    ¾çÃþ ÁöÁú¸·(å»öµ ò·òõد)
  • bimolecular lamellar lipid membrane
    À̺ÐÀÚ(ì£ÝÂí­) ÆÇ»óÁöÁú¸·(÷ùßÒò·òõد)
  • bimolecular lipid membrane
    À̺ÐÀÚ ÁöÁú¸·(ì£ÝÂí­ò·òõد)
  • black lipid membrane
    Èæ ÁöÁú¸·(ýÙò·òõد)
  • C55 lipid carrier
    "C55 ÁöÁú¿î¹Ýü(ò·òõê¡Úæô÷),(ÔÒ) bactoprenol"
  • complex lipid
    º¹ÇÕÁöÁú(ÜÜùêò·òõ)
  • compound lipid
    "È­ÇÕÁöÁú(ûùùêò·òõ), (ÔÒ) complex lipid"
  • derived lipid
    À¯µµÁöÁú(ë¯Óôò·òõ)
  • diol lipid
    ´ÙÀÌ¿ÃÁöÁú(ò·òõ)
  • high-lipid lipoprotein
    °íÁöÁú ÁöÁú´Ü¹éÁú(ÍÔò·òõò¢òõÓ±ÛÜòõ)
  • lipid
    ÁöÁú(ò·òõ)
  • lipid bilayer
    ÁöÁú¾çÃþ(ò·òõÕ×öµ)
  • lipid-globular protein mosaic model
    "ÁöÁú-±¸»ó´Ü¹éÁú(ò·òõϹßÒÓ±ÛÜòõ) , ¸ðÀÚÀÌÅ©¸ðµ¨"
  • lipid imbibition theory
    ÁöÁúÈí¼öÀÌ·Ð(ò·òõýåâ¥ìµÖå)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • lipid bound proton
    Áö¹æ°áÇվ缺ÀÚ
  • lipid-laden
    Áö¹æÀûÀç
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
PGA1-3 prostaglandins A1 to A3
PGE, PGE1, PGE2 prostaglandins E, E1, E2
PGF, PGF1, PGF2 prostaglandins F, F1, F2
CEA Carcino-Embryonic Antigen [HP 1825-6]
  ; Oncofetal Antigens
  ; Glycopro...
HIVD Herniation(Herniated) of Inter-Vertebral Disc
  - Cervical HIVD
   &...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
PGE1 Prostaglandins E1
PGF2 alpha Prostaglandins F2 alpha
PGE2 Prostaglandins E1 and E2
DRO Differential Reinforcement of Other Behaviour
MOTT Mycobacteria Other Than Tuberculosis
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • JrId: 21055
    JournalTitle: Prostaglandins & other lipid mediators.
    MedAbbr: Prostaglandins Other Lipid Mediat
    ISSN: 1098-8823
    ESSN:
    IsoAbbr: Prostaglandins Other Lipid Mediat.
    NlmId: 9808648
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • form-other
    Çü½Ä»óÀÇ ¸ñ
  • lipid bilayer
    Áö¹æÁú Ãþ
    ¼¼Æ÷¸·Àº ÁöÁú ÀÌÁß ÃþÀ̶ó Çϸç, ÀÌ Áö¹æÁú ÃþÀº ÁÖ·Î ÀÎ ÁöÁú¿¡ ÀÇÇØ ±¸¼ºµÇ¾î ÀÖ´Ù. ÀÎ ÁöÁúÀº Ä£¼ö¼º°ú ¼Ò¼ö¼º ºÎÀ§·Î ±¸¼ºµÇ¾î ¼¼Æ÷¸·ÀÇ ¹°Áú À̵¿¿¡ ¿µÇâÀ» ³¢Ä£´Ù. ¶Ç Áö¹æÁú ÃþÀÇ ÄÝ·¹½ºÅ×·ÑÀº ÀÌ ÃþÀÇ ¾ÈÁ¤È­¸¦ µ½´Â´Ù.
  • lipid metabolism
    ÁöÁú ´ë»ç
    °£¿¡¼­ ÈçÈ÷ ÀϾ¸ç Áö¹æ»êÀÇ º£Å¸-»êÈ­ ¹× ¾Æ¼¼Æ® ¾Æ¼¼Å×ÀÌÆ® Çü¼º, ´ç ÁöÁú »ý¼º, ÄÝ·¹½ºÅ×·Ñ ¹× ÀÎ ÁöÁú Çü¼º, ´ç°ú ´Ü¹éÁú·ÎºÎÅÍ Áö¹æÀÇ Àüȯ µîÀÌ °¡Àå ´ëÇ¥ÀûÀÌ´Ù.
  • lipid proteinosis
    ÁöÁú ´Ü¹éÁõ
  • lipid storage
    Áö¹æ ÀúÀå
    Áö¹æ ¼¼Æ÷°¡ ´ã´çÇÏ´Â ±â´ÉÀ¸·Î ü³»¿¡ Èí¼öµÈ Áö¹æÀº ų·Î¹ÌÅ©·ÐÀÇ ÇüÅ·Πü¼øÈ¯À» ÇÏ°Ô µÇ¸ç, Áö¹æ Á¶Á÷ÀÇ ¸ð¼¼Ç÷°ü¿¡ À̸£¸é ³»ÇÇ ¼¼Æ÷ÀÇ ´çÁöÁú ¸®ÆÄ¾ÆÁ¦ÀÇ ÀÛ¿ëÀ¸·Î À¯¸® Áö¹æ»ê°ú ´Ü´ç·ù·Î ºÐÇØµÇ¾î Áö¹æ ¼¼Æ÷¿¡ ÀÇÇØ ´Ü¼ø È®»êÀ¸·Î ¼·ÃëµÈ´Ù. ÀÌ Áö¹æ»êÀº Áö¹æ ÇÕ¼º È¿¼Ò¿¡ ÀÇÇÏ¿© Áß¼º Áö¹æÀ¸·Î ÇÕ¼ºµÇ¸ç Áö¹æ ºÐÇØ È¿¼Ò¸¦ ¾ïÁ¦ÇÏ¿© Áö¹æÀ» ÃàÀû½ÃŲ´Ù.
  • lipid-filled histocyte
    ÁöÁú·Î ä¿öÁø Á¶Á÷±¸
  • other abnormality
    ±âŸ ÀÌ»ó
  • other craniofacial disorder
    ´Ù¸¥ µÎ°³ ¾È¸é Àå¾Ö
  • other facial structure
    ´Ù¸¥ ¾È¸é ±¸Á¶¹°
  • other mycoses
    ±âŸ Áø±ÕÁõ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
other-directed Pertaining to a person readily influenced by the attitudes of others.
(05 Mar 2000)
transferases (other substituted phosphate groups) <enzyme> A class of enzymes that transfers substituted phosphate groups.
Registry number: EC 2.7.8
(12 Dec 1998)
prostaglandins A group of compounds derived from unsaturated 20-carbon fatty acids, primarily arachidonic acid, via the cyclooxygenase pathway. They are extremely potent mediators of a diverse group of physiological processes.
(12 Dec 1998)
prostaglandins a (13e,15s)-15-hydroxy-9-oxoprosta-10,13-dien-1-oic acid (pga(1)); (5z,13e,15s)-15-hydroxy-9-oxoprosta-5,10,13-trien-1-oic acid (pga(2)); (5z,13e,15s,17z)-15-hydroxy-9-oxoprosta-5,10,13,17-tetraen-1-oic acid (pga(3)). A group of naturally occurring secondary prostaglandins derived from pge. Pga(1) and pga(2) as well as their 19-hydroxy derivatives are found in many organs and tissues.
(12 Dec 1998)
prostaglandins a, synthetic Analogs or derivatives of prostaglandin a that do not occur naturally in the body. They do not include the product of the chemical synthesis of hormonal pga.
(12 Dec 1998)
prostaglandins b Physiologically active prostaglandins found in many tissues and organs. They are potent pressor substances and have many other physiological activities.
(12 Dec 1998)
prostaglandins d Physiologically active prostaglandins found in many tissues and organs. They show pressor activity, are mediators of inflammation, and have potential antithrombotic effects.
(12 Dec 1998)
prostaglandins e (11 alpha,13e,15s)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid (pge(1)); (5z,11 alpha,13e,15s)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid (pge(2)); and (5z,11 alpha,13e,15s,17z)-11,15-dihydroxy-9-oxoprosta-5,13,17-trien-1-oic acid (pge(3)). Three of the six naturally occurring prostaglandins. They are considered primary in that no one is derived from another in living organisms. Originally isolated from sheep seminal fluid and vesicles, they are found in many organs and tissues and play a major role in mediating various physiological activities.
(12 Dec 1998)
prostaglandins e, synthetic Analogs or derivatives of prostaglandins e that do not occur naturally in the body. They do not include the product of the chemical synthesis of hormonal pge.
(12 Dec 1998)
prostaglandins f (9 alpha,11 alpha,13e,15s)-9,11,15-trihydroxyprost-13-en-1-oic acid (pgf(1 alpha)); (5z,9 alpha,11,alpha,13e,15s)-9,11,15-trihydroxyprosta-5,13-dien-1-oic acid (pgf(2 alpha)); (5z,9 alpha,11 alpha,13e,15s,17z)-9,11,15-trihydroxyprosta-5,13,17-trien-1-oic acid (pgf(3 alpha)). A family of prostaglandins that includes three of the six naturally occurring prostaglandins. All naturally occurring pgf have an alpha configuration at the 9-carbon position. They stimulate uterine and bronchial smooth muscle and are often used as oxytocics.
(12 Dec 1998)
prostaglandins f, synthetic Analogs or derivatives of prostaglandins f that do not occur naturally in the body. They do not include the product of the chemical synthesis of hormonal pgf.
(12 Dec 1998)
prostaglandins g A group of physiologically active prostaglandin endoperoxides. They are precursors in the biosynthesis of prostaglandins and thromboxanes. most frequently encountered member of this group is the prostaglandin g2.
(12 Dec 1998)
prostaglandins h A group of physiologically active prostaglandin endoperoxides. They are precursors in the biosynthesis of prostaglandins and thromboxanes. The most frequently encountered member of this group is the prostaglandin h2.
(12 Dec 1998)
prostaglandins, synthetic Compounds obtained by chemical synthesis that are analogs or derivatives of naturally occurring prostaglandins and that have similar activity.
(12 Dec 1998)
anisotropic lipid A lipid in the form of doubly refractive droplets.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • lipid
    ÁöÁú
  • each other
    ¼­·Î
  • in some way or other
    ¾î¶»°Ô ÇØ¼­µçÁö
  • other
    ±×¹ÛÀÇ
  • some other time
    ¾ðÁ¨°¡ µý³¯¿¡(=some other day)
  • t'other
    ¶Ç Çϳª
  • A.N. Other
    ÀÍ¸í¾¾;¼±¼ö ¹ÌÁ¤
  • other
    µý;´Ù¸¥;´ÙÀ½ÀÇ;³ª¸ÓÁöÀÇ;every ~ Çϳª°É·¯;none ~ than ´Ù¸§ ¾Æ´Ñ;the ~ day(night)ÀÏÀü(¿äÀü³¯ ¹ã)¿¡;the ~ party »ó´ë¹æ;the ~ side (¹Ì±¹¿¡¼­ º») À¯·´;the ~ world ³»¼¼;Àú½Â
  • other
    ±×·¸Áö ¾Ê°í;µý ¹æ¹ýÀ¸·Î
  • other
    µý °Í(»ç¶÷);´Ù¸¥ Çϳª;³ª¸ÓÁö °Í;of all ~s ¸ðµç °Í(»ç¶÷)Áß¿¡¼­ ƯÈ÷;some ... or ~ ¹«¾ð(´©±º,¾îµò)°¡
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á